Kolahdooz Hanieh, Khori Vahid, Erfani-Moghadam Vahid, Livani Fatemeh, Mohammadi Saeed, Memarian Ali
Student Research Committee, Golestan University of Medical Sciences, Gorgan 49341-74515, Iran.
Department of Immunology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan 49341-74515, Iran.
Life (Basel). 2023 Apr 24;13(5):1076. doi: 10.3390/life13051076.
Psoriasis (PS) is characterized by hyperplasia of epidermis and infiltration of immune cells in the dermis. A negligible susceptibility of hypodermic permeation for local anti-inflammatory remedies is one of the major causes of medication failures. Although curcumin (CUR) has indicated effectiveness in treatment of inflammation, its successful permeation through the stratum corneum is yet a challenging issue. Therefore, niosome (NIO) nanoparticles were used as curcumin carriers to enhance its delivery and anti-inflammatory effects. Curcumin-niosome (CUR-NIO) formulations were constructed by the thin-film-hydration (TFH) technique and were added to hyaluronic acid and Marine-collagen gel-based formulation. Five mild-to-moderate PS patients (18-60 years) with PASI scores < 30 with symmetrical and similar lesions were included in the study. The prepared formulation (CUR 15 µM) was topically administered for 4 weeks on the skin lesions, in comparison to the placebo. Clinical skin manifestations were monitored and skin punches were obtained for further gene expression analyses. There was a significant reduction in redness, scaling, and an apparent improvement in CUR-NIO-treated group in comparison to the placebo-treated counterpart. The gene expression analyses resulted in significantly downregulation of IL17, IL23, IL22, and TNFα, S100A7, S100A12, and Ki67 in CUR-NIO-treated lesions. Consequently, CUR-NIO could provide therapeutic approaches for the patients with mild-to-moderate PS by suppressing the IL17/IL23 immunopathogenic axis.
银屑病（PS）的特征是表皮增生和真皮中免疫细胞浸润。局部抗炎药物皮下渗透的敏感性可忽略不计是药物治疗失败的主要原因之一。尽管姜黄素（CUR）已显示出治疗炎症的有效性，但其成功透过角质层仍是一个具有挑战性的问题。因此，脂质体（NIO）纳米颗粒被用作姜黄素载体，以增强其递送和抗炎作用。通过薄膜水化（TFH）技术构建姜黄素-脂质体（CUR-NIO）制剂，并将其添加到基于透明质酸和海洋胶原蛋白的凝胶制剂中。本研究纳入了5名年龄在18至60岁之间、PASI评分<30、皮损对称且相似的轻度至中度银屑病患者。与安慰剂相比，将制备好的制剂（CUR 15 µM）局部应用于皮损部位4周。监测临床皮肤表现，并获取皮肤活检样本进行进一步的基因表达分析。与安慰剂治疗组相比，CUR-NIO治疗组的红斑、脱屑明显减轻，且有明显改善。基因表达分析结果显示，CUR-NIO治疗的皮损中IL17、IL23、IL22和TNFα、S100A7、S100A12和Ki67显著下调。因此，CUR-NIO可以通过抑制IL17/IL23免疫致病轴为轻度至中度银屑病患者提供治疗方法。
Zotero 插件
